Newswise — (MOUNT LAUREL, NJ, April 29, 2019) As May is the national awareness month for both Amyotrophic Lateral Sclerosis and Huntington’s disease, the American Neurological Association is highlighting recent research on these conditions that has appeared in its publications, the Annals of Neurology and the Annals of Clinical and Translational Neurology.
Reporters covering these disorders may wish to speak with the authors for background on the current status of the science. Please contact Denise Portner for more information or to arrange author interviews.
About Amyotrophic Lateral Sclerosis
According to the National Institute of Neurological Disorders and Stroke, (NINDS), amyotrophic lateral sclerosis (ALS) is a group of rare neurological diseases that mainly involve the neurons responsible for controlling voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, and there is no cure for ALS and no effective treatment to halt, or reverse, the progression of the disease. In 2016, the Centers for Disease Control and Prevention estimated that between 14,000-15,000 Americans had ALS. The disease affects men and women of all races and ethnic backgrounds but is more common in Caucasians and symptoms most commonly develop between ages 55-75.
ALS Highlighted Articles:
High‐frequency motor rehabilitation in amyotrophic lateral sclerosis: a randomized clinical trial
Smoking and amyotrophic lateral sclerosis: A mendelian randomization study
Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis
Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis
About Huntington’s Disease
According to NINDS, Huntington's disease (HD) is an inherited disorder that causes brain cells (neurons), to die in various areas of the brain, including those that help to control voluntary movement. Symptoms of the disease, which gets progressively worse, include uncontrolled movements, abnormal body postures, and changes in behavior, emotion, judgment, and cognition. People with HD also develop impaired coordination, slurred speech, and difficulty feeding and swallowing. HD typically begins between ages 30 and 50. An earlier onset form called juvenile HD occurs under age 20. More than 30,000 Americans are affected by HD.
Huntington’s Disease highlighted Articles:
Cerebellar degeneration correlates with motor symptoms in Huntington disease
DNA damage signatures in peripheral blood cells as biomarkers in prodromal Huntington’s disease
In vivo characterization of white matter pathology in premanifest Huntington's disease
An image‐based model of brain volume biomarker changes in Huntington's disease
Predicting clinical diagnosis in Huntington's disease: An imaging polymarker
Xeroderma pigmentosum is a definite cause of Huntington's disease‐like syndrome
About the American Neurological Association (ANA)
From advances in stroke and dementia to movement disorders and epilepsy, the American Neurological Association has been the vanguard of research since 1875 as the premier professional society of academic neurologists and neuroscientists devoted to understanding and treating diseases of the nervous system. Its monthly Annals of Neurology is among the world’s most prestigious medical journals, and the ANA’s Annals of Clinical and Translational Neurology is an online-only, open access journal providing rapid dissemination of high-quality, peer-reviewed research related to all areas of neurology. The acclaimed ANA Annual Meeting draws faculty and trainees from the top academic departments across the U.S. and abroad for groundbreaking research, networking, and career development. For more information, visit www.myana.org or @TheNewANA1.
###
MEDIA CONTACT
Register for reporter access to contact detailsCITATIONS
Annals of Neurology; Annals of Clinical and Translational Neurology
RSS